Holen Sie sich die Stockscreener-App
1.53
0.65%
-0.01
Handel nachbörslich:
1.53
Schlusskurs vom Vortag:
$1.54
Offen:
$1.5285
24-Stunden-Volumen:
433.66K
Relative Volume:
1.91
Marktkapitalisierung:
$40.25M
Einnahmen:
$4.99M
Nettoeinkommen (Verlust:
$-28.29M
KGV:
-1.4533
EPS:
-1.0528
Netto-Cashflow:
$-36.20M
1W Leistung:
-5.56%
1M Leistung:
-0.97%
6M Leistung:
+31.90%
1J Leistung:
-3.77%
1-Tages-Spanne:
$1.50
$1.56
1-Wochen-Bereich:
$1.50
$1.63
52-Wochen-Spanne:
$0.8502
$2.093
Lava Therapeutics Nv Stock (LVTX) Company Profile
Firmenname
Lava Therapeutics Nv
Sektor
Branche
Telefon
31 6 3000 3035
Adresse
YALELAAN 62, UTRECHT
Vergleichen Sie LVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.53 | 40.51M | 4.99M | -28.29M | -36.20M | -1.0528 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-04-19 | Eingeleitet | Jefferies | Buy |
| 2021-04-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lava Therapeutics Nv Aktie (LVTX) Neueste Nachrichten
Price momentum metrics for LAVA Therapeutics N.V. explainedJuly 2025 Spike Watch & Low Risk High Win Rate Stock Picks - newser.com
How LAVA Therapeutics N.V. stock valuations compare to rivalsPortfolio Return Report & Fast Momentum Stock Entry Tips - newser.com
What indicators show strength in LAVA Therapeutics N.V.Gap Down & Entry and Exit Point Strategies - newser.com
Can LAVA Therapeutics N.V. hit a new high this monthJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Will LAVA Therapeutics N.V. stock go up soonQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
LAVA Therapeutics N.V. stock prediction for this weekDollar Strength & Weekly Stock Performance Updates - newser.com
LAVA Therapeutics N.V. Stock (LVTX) Opinions on Insider Sales and Acquisition Delays - Quiver Quantitative
Gilde Healthcare sells LAVA Therapeutics (LVTX) shares for $197,898 By Investing.com - Investing.com Canada
Gilde Healthcare sells LAVA Therapeutics (LVTX) shares for $197,898 - Investing.com
LAVA Therapeutics N.V. recovery potential after sell offPortfolio Return Report & Safe Entry Zone Identification - newser.com
Can LAVA Therapeutics N.V. rally from current levelsJuly 2025 Setups & High Yield Equity Trading Tips - newser.com
Is LAVA Therapeutics N.V. forming a reversal patternLayoff News & Expert Approved Momentum Trade Ideas - newser.com
Is LAVA Therapeutics N.V. (4PKB) stock overpriced at current multiplesJuly 2025 Momentum & Low Drawdown Momentum Ideas - newser.com
Why LAVA Therapeutics N.V. stock remains resilientTrade Signal Summary & High Win Rate Trade Tips - newser.com
Published on: 2025-10-05 06:23:52 - newser.com
Analyzing recovery setups for LAVA Therapeutics N.V. investorsJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Measuring LAVA Therapeutics N.V.’s beta against major indicesQuarterly Trade Report & High Conviction Investment Ideas - newser.com
Will LAVA Therapeutics N.V. outperform the marketJuly 2025 Setups & Entry Point Confirmation Signals - newser.com
What candlestick patterns are forming on LAVA Therapeutics N.V.Weekly Trend Recap & Daily Oversold Bounce Ideas - newser.com
How LAVA Therapeutics N.V. stock performs in rate cut cyclesJuly 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Shay Capital LLC Acquires Significant Stake in LAVA Therapeutics NV - GuruFocus
LAVA Therapeutics Extends Tender Offer Deadline - TipRanks
XOMA Royalty extends tender offer deadline for LAVA Therapeutics By Investing.com - Investing.com Australia
XOMA Royalty extends tender offer deadline for LAVA Therapeutics - Investing.com India
XOMA Royalty Corporation Extends Tender Offer for LAVA Therapeutics Shares Until October 17, 2025 - Quiver Quantitative
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - GlobeNewswire
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - Benzinga
75% CVR: XOMA Royalty Extends Tender Offer for LAVA, Extended to Oct. 17 - Stock Titan
What drives LAVA Therapeutics NV stock priceBollinger Bands Signals & High-Risk, High-Reward? We Find the Winners - earlytimes.in
LAVA Therapeutics Postpones EGM for XOMA Deal - MSN
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 - GlobeNewswire
LAVA Therapeutics Cancels Extraordinary General Meeting to Finalize XOMA Royalty Acquisition Details - Quiver Quantitative
Biotech Deal Update: LAVA Therapeutics Postpones XOMA Acquisition Vote to Address Cash Position - Stock Titan
Finanzdaten der Lava Therapeutics Nv-Aktie (LVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lava Therapeutics Nv-Aktie (LVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 09 '25 |
Sale |
1.56 |
48,169 |
75,144 |
5,344,047 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 08 '25 |
Sale |
1.57 |
28,954 |
45,458 |
5,392,216 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
2,370,533 |
3,322,065 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
532,870 |
746,764 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
362,806 |
540,291 |
2,736,644 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
366,111 |
527,859 |
2,370,533 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 16 '25 |
Sale |
1.53 |
307,707 |
471,776 |
3,099,450 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
226,726 |
337,640 |
761,661 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
228,791 |
329,871 |
532,870 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 16 '25 |
Sale |
1.53 |
192,293 |
294,824 |
988,387 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):